Welcome to our dedicated page for Elevation Oncolo news (Ticker: ELEV), a resource for investors and traders seeking the latest updates and insights on Elevation Oncolo stock.
Elevation Oncology reported developments tied to its oncology drug-development business, including antibody-drug conjugate programs for solid tumors. Company updates covered EO-1022, a HER3 ADC designed with seribantumab, an MMAE payload and glycan site-specific conjugation, as well as the discontinued EO-3021 Claudin 18.2 ADC program for gastric and gastroesophageal junction cancers.
Recurring news also included financial results, research presentations, program prioritization, workforce restructuring, strategic alternatives, material agreements, governance matters and capital-structure developments. Later corporate-status disclosures documented the company’s acquisition process, Nasdaq delisting and termination of Exchange Act registration.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Elevation Oncology has announced the selection of an abstract for SYSA1801 (EO-3021) Phase 1 clinical data for presentation at the ASCO 2023 Annual Meeting in Chicago, from June 2-6, 2023. The ongoing Phase 1 study is focused on evaluating SYSA1801 in patients with Claudin 18.2-positive advanced solid tumors, conducted in partnership with CSPC Pharmaceutical Group in China. Elevation plans to advance its clinical trial for EO-3021 in the U.S. in the second half of 2023. EO-3021 targets Claudin 18.2, a significant unmet need in oncology, particularly for gastric and pancreatic cancers, with no existing approved therapies. The U.S. FDA has cleared an Investigational New Drug application for EO-3021.
Elevation Oncology (Nasdaq: ELEV) recently presented preclinical data for its lead candidate EO-3021 targeting Claudin 18.2 at the AACR Annual Meeting 2023. The antibody-drug conjugate displayed anti-tumor efficacy in various cancers like gastric and pancreatic in preclinical models. Notably, EO-3021 achieved a confirmed partial response in a patient with metastatic gastric cancer during a Phase 1 trial in China, showing a 66.7% tumor reduction over approximately 11 months of treatment. The company plans to initiate a US Phase 1 clinical trial in the latter half of 2023, further advancing EO-3021's development aimed at addressing significant unmet medical needs in oncology.
Elevation Oncology (Nasdaq: ELEV) has announced it will present preclinical proof-of-concept data for its drug candidate EO-3021 at the AACR Annual Meeting 2023 in Orlando, Florida, from April 14-19, 2023. The oral presentation is scheduled for April 17, showcasing EO-3021, an antibody-drug conjugate targeting Claudin 18.2, which may become a leading treatment for solid tumors. Additionally, two posters will detail findings from a Phase 2 CRESTONE study on NRG1 fusions. The company aims to initiate a Phase 1 clinical trial for EO-3021 in the U.S. in the latter half of 2023.